Fundraising FoxAdvent Life Sciences — 2017 Investments
3 investments dated 2017 · listed companies and verified rows first · show all
Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Michael Gilman(Executive Officer, Director)inMark DeLong(CEO)inDavid Neafus(Executive Officer)inRussell C. Petter(Executive Officer)
BoardColleen Cuffaro(Director)inAlan E. Walts(Director)in
Board seatRaj ParekhAlan Walts· per SEC Form D
Co-investorsCanaan PartnersPfizer VenturesHBM Healthcare InvestmentsHBM PartnersNextech InvestOUP (Osage University Partners)+2 more
Iterum Therapeutics develops anti-infective compounds to treat infections caused by multi-drug resistant pathogens.
BiotechDigital HealthHealthtechMedical DevicesDublin, US
Michael W. Dunne(Executive Officer, Promoter)inCorey N. Fishman(Executive Officer, Director, Promoter)inJudith M. Matthews(Executive Officer, Promoter)Jeff Schaffnit(Executive Officer)
BoardBrenton K. Ahrens(Director)Ronald M. Hunt(Director)
Co-investorsBay City CapitalCanaan PartnersSofinnova VenturesDolby Family VenturesFrazier Life SciencesSofinnova Venture Partners
Co-investorsFountain Healthcare PartnersOrbiMedColumbus Venture PartnersForbionRedwood Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.